Latest filing published 24 Feb 2026 for Halozyme Therapeutics, INC..
Insider track record
No signal scores available.
Mark Howard Snyder: trading record in brief
Mark Howard Snyder discloses dealings in Halozyme Therapeutics, Inc. to SEC (Form 4). Between 3 January 2023 and 23 February 2026, the trades on record add up to 26 filings.
None of the filings is a plain purchase or sale on the open market; they cover grants, option exercises and other movements. Because grants and exercises are largely decided by remuneration plans, they are not counted as purchases here.
The latest filing, published on 24 February 2026, reports an option exercise in Halozyme Therapeutics, Inc. The median gap between a trade and its publication by SEC (Form 4) is 2 days. Section 16 rules allow two business days to file each Form 4. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Companies and markets linked to Mark Howard Snyder
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 5,332 shares0Common StockSEC:0001159036-26-000030:0
- 4,796 shares0Common StockSEC:0001159036-26-000027:0
- 7,611 shares0Common StockSEC:0001159036-26-000005:0
- 5,035 shares0Common StockSEC:0001415889-25-017270:0
- 7,012 shares0Common StockSEC:0001415889-25-005306:0
- 17,409 shares0Common StockSEC:0001415889-25-004508:0
- 7,611 shares0Common StockSEC:0001415889-25-000811:0
- 4,796 shares0Common StockSEC:0001415889-24-004476:0
- 7,611 shares0Common StockSEC:0001415889-24-000768:0
- 7,611 shares0Common StockSEC:0001415889-23-000393:0
10 of 10 declarations
